• Home
  • Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.

Author List
Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF
Publication
Neuro-oncology advances
Publication ID (Profile URL)
https://researcherprofiles.org/profile/220906534
Publication Year
2021
PubMed ID
34377989
Publication Title
Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082.